EMD Serono Expands Access to IVF Medications in 2026, Boosting Global Cycle Volumes

In a major policy and corporate milestone in February 2026, EMD Serono announced new patient access pathways for its fertility medication portfolio, including Gonal-f®. Partnering with new US federal purchasing platforms, the initiative drastically lowers out-of-pocket costs for patients pursuing in vitro fertilization (IVF).

Business Insight: Medication costs are a primary barrier to fertility treatments. By reducing these expenses, patient volumes are expected to surge across North America. B2B stakeholders, equipment manufacturers, and international clinics exhibiting at CMTF must scale their clinical capacity and invest in high-throughput laboratory automation to meet this incoming wave of newly enfranchised patients.

【 Keywords】 #IVFMedications #FertilityMarket #CMTF2026

【Source Link】 https://www.emdserono.com/us-en/company/news/press-releases/advanced-patient-access-to-ivf-medicines-in-the-us-06-02-2026.html